XML 132 R75.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2016 | Jul. 03, 2016 | Apr. 03, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Nov. 10, 2017 | Oct. 01, 2017 | Jun. 30, 2017
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | $ 3,103 |  | $ 337 | $ 869 |  |  |
Other asset impairment charges |  |  |  |  | 13 |  |  |  |  |  |
Equity method investment, other than temporary impairment |  | $ 241 | $ 130 | $ 81 |  |  |  | 452 |  |  |
Operating Segments [Member] | Essential Health Segment [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 840 |  |  |
Operating Segments [Member] | Innovative Health Segment [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 29 |  |  |
In Process Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments | [1] |  |  |  | 214 |  |  |  |  |  |
In Process Research and Development [Member] | Multi-Antigen Vaccine For Spinal Fusion Surgery [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | 117 |  |  |  |  |  |
In Process Research and Development [Member] | Hospira [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 265 |  |  |
In Process Research and Development [Member] | InnoPharma [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 128 |  |  |
Other In Process Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 110 |  |  |
Other In Process Research and Development [Member] | Hospira [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 81 |  |  |
Other In Process Research and Development [Member] | InnoPharma [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | 17 |  |  |  |  |  |
Other In Process Research and Development [Member] | King [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | 29 |  |  |
AM Pharma BV [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Impairment of investment |  |  |  |  |  |  | $ 43 |  |  |  |
Hisun Pfizer Pharmaceuticals Co. Ltd [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity method investment, other than temporary impairment |  |  |  |  |  |  |  | $ 452 |  |  |
Equity method investment, ownership percentage |  | 49.00% |  |  |  |  | 49.00% | 49.00% | 49.00% |  |
Laboratorio Teuto Brasilero [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity method investment, other than temporary impairment |  |  |  |  |  |  |  | $ 50 |  |  |
Equity method investment, ownership percentage |  | 40.00% |  |  |  |  |  | 40.00% |  | 40.00% | 40.00%
Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | 2,647 | [1] | $ 20 |  |  |  |
Developed Technology Rights [Member] | Hospira [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  |  | $ 366 |  |  |
Developed Technology Rights [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  | 127 |  |  |  |
Developed Technology Rights [Member] | Hospira [Member] | Sterile Injectable Pain Reliever [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  | 124 |  |  |  |
Developed Technology Rights [Member] | Hospira [Member] | Generic Injectable Pain Reliever [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  | 26 |  |  |  |
Developed Technology Rights [Member] | NextWave [Member] | Treatment Of Attention Hyperactivity Disorder [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  |  |  | $ 39 |  |  |  |
Developed Technology Rights [Member] | Operating Segments [Member] | Essential Health Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | 2,600 |  |  |  |  |  |
Developed Technology Rights [Member] | Operating Segments [Member] | Innovative Health Segment [Member] | Anacor [Member] | Treatment For Toenail Fungus [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | 31 |  |  |  |  |  |
Licensing Agreements [Member] | Operating Segments [Member] | Essential Health Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | 242 |  |  |  |  |  |
In Process Research and Development [Member] | Operating Segments [Member] | Essential Health Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member] |  |  |  |  |  |  |  |  |  |  |
Schedule of Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |
Intangible asset impairments |  |  |  |  | $ 80 |  |  |  |  |  |
[1] | Reflects intangible assets written down to fair value in 2018. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

X
- Definition [Line Items] for Intangible Assets [Table] + References No definition available. + Details
Name: | pfe_IntangibleAssetsLineItems
Namespace Prefix: | pfe_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=114001220&loc=d3e32787-111569 + Details
Name: | us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cumulative impairment loss on investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details
Name: | us-gaap_OtherAssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_OtherInProcessResearchandDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_KingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AMPharmaBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenericSterileInjectableProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SterileInjectablePainRelieverMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenericInjectablePainRelieverMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_NextWaveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TreatmentOfAttentionHyperactivityDisorderMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TreatmentForToenailFungusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |